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Abstract
Introduction and Objectives: Few extensive studies have assessed the effects
of botulinum neurotoxin A in adults with upper limb spasticity (ULS) poststroke/
traumatic brain injury (TBI) on muscle tone, spasticity, active range of motion
(AROM), and function. The aim of this study was to assess the efficacy and safety
of abobotulinumtoxinA (Dysport) in hemiparetic adults with ULS poststroke/TBI.
Methods: In this phase 3, prospective, double-blind, placebo-controlled study,
243 patients (34 sites, 9 countries) were randomly assigned (1:1:1) to Dysport
500 or 1000 U or placebo. The primary objective was assessment of upper limb
muscle tone (Modified Ashworth Scale; MAS) in the primary targeted muscle
group (PTMG; finger, wrist, or elbow flexors). Other measures included spasticity
(Tardieu Scale), AROM, ease of applying splint (EOS), clinical benefit (Physician
Global Assessment; PGA), and subjective function (Disability Assessment Scale;
DAS). Results: Four weeks postinjection, a highe...
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IntroductIon and objectIves
  Intramuscular injection of botulinum toxin A (BoNT-A) is recommended as a first-line treatment to reduce muscle 
tone (resistance to passive movement) in patients with focal spastic paresis.
  However, few extensive studies have assessed the effects of BoNT-A on muscle tone, active range of motion (AROM) 
and function in adults with upper limb spasticity (ULS) after stroke or traumatic brain injury (TBI).
  The aim of this study was to assess the efficacy and safety of abobotulinumtoxinA (Dysport®) in hemiparetic adults 
with ULS ≥6 months after stroke or TBI. Modifications in muscle tone and movement with abobotulinumtoxinA in the 
spastic upper limb are the focus of this poster. 
 
Methods
  This was a Phase III, prospective, double-blind, placebo-controlled study of 243 patients (from 34 sites in 9 countries) 
randomized (1:1:1) to abobotulinumtoxinA 500 or 1000 units (U) or placebo (Figure 1).
  The primary endpoint was change in the Modified Ashworth Scale (MAS)1 in the primary target muscle group (PTMG; 
finger, wrist or elbow flexors).
  Secondary endpoints included: 
 •  Physician Global Assessment (PGA; 9-point scale from -4 [markedly worse] to 4 [markedly improved]).
 • Disability Assessment Scale (DAS).2,3
  •  Tardieu scale (angle of arrest at slow speed [X
V1
], angle of catch at fast speed [X
V3
] and spasticity angle [X; 
defined as X
V1
-X
V3
]).
  • Active range of motion (AROM).
  •  Ease of applying a splint (6-point scale from 0 [no splint needed] to 5 [splint needed but unable to apply]).
  Inclusion criteria were as follows:
 •  Age 18–80 years.
 •  One clinically defined stroke episode (WHO criteria) or one episode of brain trauma.
 •  ≥6 months post-stroke or TBI.
 •  MAS ≥2 in PTMG for toxin-naïve patients or MAS ≥3 in PTMG for toxin non-naïve patients.
 •  DAS score ≥2 on principal target of treatment (PTT; limb position, dressing, hygiene or pain).
 •  Spasticity angle ≥10° in PTMG.
 •  Modified Frenchay Scale overall score 1-8.
 
results
  Baseline characteristics were well balanced across groups (Table 1). Extrinsic finger flexors were the most often 
targeted muscle group.
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conclusIon
  This is the first international large study reporting a significant improvement of muscle tone (MAS) and clinical 
benefit (PGA; independent of MAS), together with a clinically meaningful improvement in active range of 
motion and an objective reduction in spasticity (Tardieu scale), associated with abobotulinumtoxinA (Dysport®; 
500U and 1000U) in the hemiparetic upper limb.
  The efficacy of abobotulinumtoxinA was observed as early as 1 week after injection and continued for 12 weeks, 
and provided benefit for up to 20 weeks in some patients.
  The higher dose  of 1000 U provided additional benefit on active range of motion and perceived function (DAS).
  Safety profile was consistent with the known profile of abobotulinumtoxinA in this disorder.
  This study undertook training of all raters using in-person and/or video training with real patients, which led to 
standardization of the use of the 2 main scales used: MAS and Tardieu and the measurement of the active range 
of motion. This process likely contributed to less variation between rating sessions. 
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  More patients had a PGA score ≥1 (at least ‘slightly improved’) at 4 weeks in the abobotulinumtoxinA 500U and 
1000U groups (75.0% and 87.3%, respectively; p<0.001) compared with placebo (40.5%). Likewise, more patients 
had a PGA score ≥2 (at least ‘improved’) at 4 weeks in the abobotulinumtoxinA 500U and 1000U groups (45.0% and 
57.0%, respectively; p<0.01) compared with placebo (25.3%).
  More patients in the 1000U group (62.0%) than in the placebo group (39.2%) improved on DAS as measured by ≥1 
grade decrease from baseline to week 4 for the PTT (p<0.01; Figure 6).
  Limb position was the domain most frequently chosen as PTT and more patients receiving abobotulinumtoxinA 500U 
or 1000U achieved ≥1 grade decrease in that domain at week 4 than with placebo (placebo; 29.1%, 500U; 36.3%, 
p<0.05; 1000U; 50.6%, p<0.001).
safety profile
  No adverse events were reported that were inconsistent with the known published safety profile of 
abobotulinumtoxinA (Table 3).
  No deaths or serious adverse events were assessed as being related to treatment.
Table 3  Any adverse events after injection (>3% in any group) 
Adverse event Placebo
(n=81)
ABO 500U
(n=81)
ABO 1000U
(n=81)
Nasopharyngitis 1 (1.2) 7 (8.6) 1 (1.2)
Muscle weakness in injected limb 2 (2.5) 2 (2.5) 4 (4.9)
Injection site pain 3 (3.7) 1 (1.2) 0 (0)
Increased blood triglycerides 0 (0) 3 (3.7) 1 (1.2)
Nausea 0 (0) 3 (3.7) 0 (0)
Data are presented as number of patients (percentage of patients); ABO: abobotulinumtoxinA
Table 2  Mean change from baseline to Week 4 in X
V1
, X
V3
 and X for all muscle groups
X
V1
: angle of arrest. X
V3
: angle of catch. X: spasticity angle. SEM: standard error mean. p-values are versus placebo.
Finger flexors
Mean (SEM)
Wrist flexors
Mean (SEM)
Elbow flexors
Mean (SEM)
Tardieu scale
Placebo 1.9 (3.3) 4.4 (3.0) -0.5 (1.5)
X
V1 
(o)            500U 12.0 (3.5) p=NS 10.8 (2.1) p<0.05 2.1 (0.7) p=NS
1000U 18.2 (4.1) p<0.01 12.2 (2.3) p<0.01 1.0 (1.0) p=NS
Placebo 9.8 (5.1) 2.5 (2.7) 4.5 (1.9)
X
V3 
(o)            500U 39.3 (6.3) p<0.001 27.1 (4.0) p<0.001 19.6 (3.2) p<0.001
1000U 47.7 (5.6) p<0.001 34.7 (3.6) p<0.001 25.7 (4.2) p<0.001
Placebo -7.9 (5.4) 1.9 (2.3) -5.0 (2.2)
X
 
(o)              500U -27.3 (5.9) p<0.01 -16.4 (4.5) p<0.01 -17.5 (3.2) p<0.05
1000U -29.5 (5.9) p<0.01 -22.5 (3.9) p<0.001 -24.7 (4.2) p<0.001
Figure 2  Responders to abobotulinumtoxinA or placebo according to a MAS ≥1 grade improvement
MAS: Modified Ashworth Scale. ABO: abobotulinumtoxinA
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Figure 6 DAS for the PTT (≥1 grade decrease)
ABO: abobotulinumtoxinA. DAS: Disability Assessment Scale. PTT: Principal Target of Treatment
Change from baseline (ABO vs. placebo): *p<0.05; **p<0.01; ****p<0.0001
Active range of motion was measured in patients for which finger flexors were the PTMG
Figure 3 Active range of motion against finger flexors
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Figure 4 Active range of motion against wrist flexors
Change from baseline (ABO vs. placebo): *p<0.05
Active range of motion was measured in patients for which wrist flexors were the PTMG
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Figure 5 Active range of motion against elbow flexors
Change from baseline (ABO vs. placebo): *p<0.05
Active range of motion was measured in patients for which elbow flexors were the PTMG
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ABO: abobotulinumtoxinA
Figure 1  Study design
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Table 1  Baseline patient and disease characteristics
Baseline characteristics Placebo 
(n=79)
ABO 500U
(n=80)
ABO 1000U
(n=79)
Mean (SD) age, years 52.7 (13.9) 52.8 (12.9) 52.8 (13.7)
Male/female ratio, % 62/38 65/35 66/34
Stroke, % 88.6 90.0 92.4
TBI, % 11.4 10.0 7.6
Primary target muscle group (PTMG), %
Extrinsic finger flexors 51.9 55.0 60.8
Elbow flexors 29.1 31.3 24.1
Wrist flexors 19.0 13.8 15.2
ABO: abobotulinumtoxinA. TBI: traumatic brain injury
  The mean reduction (improvement) in MAS score of the PTMG from baseline to week 4 was significantly greater with 
abobotulinumtoxinA 500U and 1000U versus placebo.
  One, four and twelve weeks after injection of abobotulinumtoxinA 500U and 1000U, a higher proportion of patients 
achieved a ≥1 grade improvement in MAS than with placebo (Figure 2).
  In the abobotulinumtoxinA groups, 35.0% (500U) and 36.7% (1000U) improved MAS by ≥2 grades, vs 3.8% in the 
placebo group after 4 weeks.
  Four weeks after injection of abobotulinumtoxinA 500U and 1000U, improvements were observed using the Tardieu 
scale in finger, wrist and elbow flexors in:
 • passive range of motion (angle of arrest X
V1
)
 • angle of catch (X
V3
)
 • spasticity angle (X) (Table 2).
  AROM was improved with abobotulinumtoxinA 1000U after 4 weeks in all muscle groups. AROM of the finger flexors 
was also improved with abobotulinumtoxinA 500U after 4 weeks (Figures 3-5). 
  After 4 weeks, ease of applying splints did not change in the placebo group but was significantly improved in the 
abobotulinumtoxinA 500U and 1000U groups: -0.3 decrease (p=0.0159 and p=0.0189 versus placebo, respectively).
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